Achieving Biocompatible SABRE: An in vitro Cytotoxicity Study

  • Anand Manoharan
  • , Peter J. Rayner
  • , Wissam Iali
  • , Michael J. Burns
  • , V. Hugh Perry
  • , Simon B. Duckett*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Abstract

Production of a biocompatible hyperpolarized bolus for signal amplification by reversible exchange (SABRE) could open the door to simple clinical diagnosis via magnetic resonance imaging. Essential to successful progression to preclinical/clinical applications is the determination of the toxicology profile of the SABRE reaction mixture. Herein, we exemplify the cytotoxicity of the SABRE approach using in vitro cell assays. We conclude that the main cause of the observed toxicity is due to the SABRE catalyst. We therefore illustrate two catalyst removal methods: one involving deactivation and ion-exchange chromatography, and the second using biphasic catalysis. These routes produce a bolus suitable for future in vivo study.

Original languageEnglish
Pages (from-to)352-359
Number of pages8
JournalChemMedChem
Volume13
Issue number4
DOIs
StatePublished - 20 Feb 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2018 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.

Keywords

  • SABRE
  • biocompatibility
  • biphasic catalysis
  • cytotoxicity
  • hyperpolarization

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • General Pharmacology, Toxicology and Pharmaceutics
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'Achieving Biocompatible SABRE: An in vitro Cytotoxicity Study'. Together they form a unique fingerprint.

Cite this